Midostaurin, an orally active indolocarbazole, provides low-nanomolar, reversible inhibition of protein kinase C, vascular endothelial growth factor receptor, fms-like tyrosine kinase 3, platelet-derived growth factor receptor, and c-Kit, driving antiproliferative, pro-apoptotic, anti-angiogenic effects and upregulating endothelial nitric oxide synthase.
Usually ships within 24 hours.